Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory TherapeuticsGlobeNewsWire · Oct 7, 2026
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor ConferenceGlobeNewsWire · Sep 21, 2026
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment ConferenceGlobeNewsWire · Sep 3, 2026
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced ThrombocytopeniaGlobeNewsWire · Aug 31, 2026
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering ProcessGlobeNewsWire · Aug 13, 2026
Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor's Phase 3 DiscontinuationGlobeNewsWire · Aug 3, 2026Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$1.42 | -$1.14 | Beat |
| May 7, 2026 | -$1.51 | -$1.04 | Beat |
| Mar 31, 2026 | -$1.17 | -$1.41 | Miss |
| Nov 10, 2025 | -$1.55 | -$1.31 | Beat |
| Aug 11, 2025 | -$1.60 | -$1.87 | Miss |
| May 8, 2025 | -$1.64 | -$2.09 | Miss |